Developer docs
API playgroundTry for free, no card

Search company profiles

AnchorDx

Full company profile

uuid000348g

Namestring
AnchorDx
Legal namestring
广州市基准医疗有限责任公司 (Guangzhou AnchorDx Medical Co., Ltd.)
Websiteurl
anchordx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

AnchorDx is a precision medicine company headquartered in Guangzhou, China, founded in 2015. The company develops liquid biopsy tests based on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) methylation sequencing for early cancer detection, with products built on a "one tube of blood" or "one tube of urine" sample workflow. Its commercial lead product is UriFind, a urine-based test for bladder and urothelial cancer, supported by PulmoSeek Plus for lung cancer and an expanding pipeline covering gastric (Gastromia) and breast cancers, plus a Twist Bioscience-enabled pan-cancer product.

The underlying technology stack combines wet-lab methylation sequencing with proprietary AI-driven classification. AnchorDx operates four named technology platforms — AnchorIRIS, AnchorViola, AnchorMonarch, and DeepMeth — supporting methylation profiling, NGS-based sequencing, bioinformatics analysis, and machine-learning-based cancer classification. The company maintains two R&D centers (Guangzhou, China, and Fremont, California) and two GMP/ISO 13485-certified production facilities. It has filed 82 patent applications with 32 granted, and its PulmoInsight algorithm was trained on more than 20,000 cases and presented at AAAI 2022.

Commercially, AnchorDx operates a hybrid business model: B2B sales of IVD kits to tertiary hospitals (100+ hospitals for UriFind, 94 for PulmoSeek Plus), laboratory-developed test (LDT) services through its own lab, and a direct-to-consumer (DTC) testing service that has cumulatively served over 100,000 people. Revenue mechanics are split across IVD kit unit sales, per-test LDT fees, and DTC test pricing. The company holds NMPA Class III IVD approval (Feb 2024), FDA Breakthrough Device Designation (July 2021), and EU CE Mark, and is pursuing a US PMA trial. It has raised approximately $83M cumulatively, including a $40M Series C in 2021, and entered a global distribution partnership with DiaCarta in February 2024.

Short descriptiontext

AnchorDx is a Guangzhou-based precision medicine company developing ctDNA and cfDNA methylation-based liquid biopsy tests for early cancer detection, serving hospitals and patients across bladder, urothelial, lung, breast, and gastric cancer indications in China and globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer early detection, DNA methylation diagnostics, liquid biopsy tests, IVD reagent kits, clinical laboratory services
Industry8 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
No data
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1IVD Reagent Kit Sales (UriFind®)
TypeOne Time License
Description

Sale of the "Human ONECUT2/VIM Gene Methylation Test Kit (Fluorescent PCR Method)" (国械注准20243400221), China's first NMPA Class III-approved IVD kit for urothelial cancer auxiliary diagnosis, launched in early 2024. Distributes via commercial channels to hospitals and clinical labs in China. One-time product/license sale per unit.

2Clinical Laboratory Testing Services (LDT)
TypeProfessional Services
Description

AnchorDx Clinical Laboratory (Guangzhou), established 2016, performs DNA methylation-based early cancer detection testing services (LDT mode) for lung, bladder, urothelial, and other cancers. Authorized in 2017 to apply high-throughput sequencing to clinical applications (one of the first such approved labs in China). Per-test service revenue from hospitals, clinicians, and direct consumers.

anchordx.com
3Direct-to-Consumer Cancer Screening Tests
TypeUsage Based
Description

Online/offline ordering of UriInstant™ (尿立检) and UriFind® (泌益检) urine-based bladder cancer screening and diagnostic products, with home self-sampling kits and 100ml urine collection; includes report interpretation and follow-up services. Per-test usage-based revenue from individual consumers.

anchordx.com
4Global Out-licensing and Co-Commercialization
TypeLicensing Royalties
Description

Long-term partnership with DiaCarta for joint development and global commercialization of cancer screening products in the U.S. and other markets. Generates licensing royalties, milestone payments, and/or co-commercialization revenue as UriFind® and other products proceed through U.S. PMA and ex-China approvals.

anchordx.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure, Others
Pricing details2 tiers
1Quote-based pricing; customers contact via 400 hotline or online order to obtain per-test and per-kit prices for UriFind/UriInstant screening products
ModelOtherBilling cadencePay-as-you-go
Notes

No public price list; tests are ordered by phone (400-930-0052) or online and pricing is provided on a quote basis.

anchordx.com
2Quote-based IVD kit pricing for hospital/lab buyers of the UriFind® ONECUT2/VIM methylation test kit (NMPA Class III)
ModelOtherBilling cadenceOne time/ perpetual license
Notes

Pricing of the Class III IVD reagent kit (国械注准20243400221) is not publicly disclosed; sold via commercial channels to hospitals and clinical labs post-2024 NMPA approval.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1PulmoSeek™ Plus (费益检®)
Description

Non-invasive liquid biopsy combined with CT imaging AI to distinguish benign and malignant pulmonary nodules. ctDNA methylation-based diagnostic product.

anchordx.com
+8 more records
Core offering1 text field

AnchorDx is a precision medicine company that develops and commercializes DNA methylation-based in-vitro diagnostic (IVD) kits and laboratory-developed tests (LDT) for non-invasive early detection of cancer. Its portfolio covers more than 70% of high-incidence cancers through "a tube of blood" products (e.g., PulmoSeek Plus for lung nodules) and "a tube of urine" products (e.g., UriFind for urothelial carcinoma and UriInstant for bladder cancer screening), supported by its in-house clinical laboratory and AI imaging tools. The company is anchored by three proprietary technology platforms — AnchorIRIS methylation library prep, AnchorViola somatic mutation library prep, and AnchorMonarch methylation analysis software — combined with the DeepMeth deep-learning model and PulmoInsight CT AI.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • PulmoSeek Plus: 98.1% sensitivity, 91.7% specificity, 97.3% accuracy for pulmonary nodule benign/malignant classification
+9 more records
Product overview1 text field

AnchorDx (广州市基准医疗有限责任公司) operates a single integrated cancer-early-detection platform built on two diagnostic "lines" — "a tube of blood" and "a tube of urine" — that together cover more than 70% of high-incidence cancers. The portfolio is unified by three proprietary technology pillars — AnchorIRIS® (methylation library prep), AnchorViola® (somatic-mutation library prep) and AnchorMonarch® (AI-driven methylation analysis software) — and is delivered through three product families: (1) the Respiratory / Lung-nodule line, led by the flagship PulmoSeek™ Plus (费益检®) blood-based methylation + CT-imaging AI test, complemented by PulmoPath™ (费镜检™) for bronchoalveolar lavage and PulmoInsight™ (费影检™) for CT-imaging AI; (2) the Urinary / Urothelial-cancer line, led by UriFind® (泌益检™) — China's first NMPA-approved IVD for urothelial cancer auxiliary diagnosis (Class III, Feb 2024) — and the early-screening test UriInstant™ (尿立检™); and (3) the Digestive / Gastric-cancer pipeline, anchored by Gastromia™ (胃易检). AnchorDx also co-developed a pan-cancer methylation assay with Twist Bioscience, runs the AnchorDx Clinical Laboratory for centralized LDT service, and uses its Guangzhou International Bio Island facilities plus a US R&D center in Fremont, California, to drive both domestic commercialization and global registration.

Product and service8 records
1UriFind® (泌益检) — Human ONECUT2/VIM Gene Methylation Test Kit
CategoryIn-vitro Diagnostic (IVD) Reagent Kit — Urothelial/Urological Cancer
Description

A urine-based DNA methylation test (ONECUT2/VIM gene methylation, fluorescent PCR method) for non-invasive auxiliary diagnosis of urothelial carcinoma (bladder, ureteral, and renal pelvis cancers). Requires 100 ml of random urine. NMPA Class III-approved, US FDA Breakthrough Device Designation, EU IVDD CE Mark. Sold to hospitals and clinical labs in China and to global partners.

2UriInstant™ (尿立检) — Urothelial Cancer Early Screening Test
CategoryLDT Cancer Screening Test — Urothelial Cancer
Description

Non-invasive urine-based genetic test for early screening of urothelial tumors covering three urinary tract cancers (bladder urothelial carcinoma, renal pelvis carcinoma, ureteral carcinoma). Designed for at-home self-sampling. Performance validated in approximately 20,000 real-world cases. Available through hospital orders and direct-to-consumer online/offline ordering.

3PulmoSeek™ Plus (费益检®) — Pulmonary Nodule Benign/Malignant Test
CategoryLDT Cancer Diagnostic — Lung/Pulmonary Nodule
Description

Non-invasive liquid biopsy test combining 10 ml peripheral blood ctDNA methylation (NGS) with chest CT-imaging AI to differentially diagnose benign vs malignant pulmonary nodules of 5–30 mm. Sensitivity 98.1%, specificity 91.7%, accuracy 97.3%. Sample: 10 ml blood + CT-DICOM data. ISO 13485:2016 certified; EU IVDD CE Mark. Sold to hospitals, with direct-to-consumer ordering available.

4PulmoPath™ (费镜检™) — Early Lung Cancer BALF/Biopsy Methylation Test
CategoryLDT Cancer Diagnostic — Lung (Biopsy/BALF)
Description

Early lung cancer auxiliary methylation test for bronchoalveolar lavage fluid (BALF) and biopsy tissue samples, designed to improve the diagnostic yield of bronchoscopy and percutaneous lung biopsy. Sensitivity 84.1%, positive predictive value 92.5%. Co-developed with West China Hospital, Sichuan University.

5PulmoInsight™ (费影检™) — AI Lung Nodule CT Imaging Analysis
CategoryAI Imaging Software — Lung/Pulmonary Nodule
Description

CT-imaging AI software that automatically detects, segments, tracks, and risk-stratifies pulmonary nodules. Trained on 20,000+ pathologically confirmed lung nodule CT cases. Reports 95% detection rate, approximately 30-second automated analysis, and 0.001 mm³ volume precision. Accepts CT-DICOM input; intended for pulmonary nodule patients and LDCT screening populations.

6AnchorDx Clinical Laboratory (Guangzhou) — LDT Clinical Testing Service
CategoryClinical Laboratory Testing Service
Description

High-standard clinical laboratory on Guangzhou International Bio Island performing DNA methylation-based cancer early-screening and early-diagnosis testing services for lung, bladder, urothelial, and other cancers. Has passed NCCL/CAP proficiency testing for six consecutive years. Serves hospitals, clinicians, and individual consumers.

7Gastromia™ (胃易检) — Gastric Cancer Non-invasive Methylation Assay
CategoryPipeline LDT — Gastric/Digestive Cancer
Description

Non-invasive blood-based ctDNA methylation assay for early detection of gastric cancer built on a 7-marker methylation panel. Overall sensitivity 87.3%, specificity 66.2%, 99.6% NPV at 2% prevalence, 80% sensitivity for early-stage gastric cancer. Co-developed with Guangdong Provincial People's Hospital and Southern Medical University.

8Twist–Anchor Methylation Pan-Cancer Detection Product
CategoryPan-Cancer Methylation Screening Test
Description

Pan-cancer cfDNA methylation high-throughput sequencing assay co-developed with Twist Bioscience, launched globally. Combines Twist's silicon-chip DNA synthesis platform with AnchorDx's methylation wet lab and AI capabilities.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

Long-term collaboration between AnchorDx and DiaCarta (Pleasanton, CA) for joint product development and global commercialization of cancer screening tests, leveraging complementary DNA methylation (AnchorDx) and mutation detection (DiaCarta QClamp®, XNA-NGS OptiSeq™) technologies. DiaCarta is also a clinical testing laboratory in AnchorDx's U.S. UriFind® PMA registrational trial (NCT05643690). The partnership is part of AnchorDx's stated strategy to accelerate global commercialization of UriFind® and future cancer screening products.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-01-01
Description

AnchorDx's U.S. registrational clinical trial (NCT05643690) for UriFind® PMA application plans to enroll more than 1,000 patients across 10 urology centers and 3 CAP/CLIA-certified laboratories (DiaCarta is one of them), with first patient enrolled. Trial results will be submitted to the U.S. FDA for Premarketing Approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-01
Description

Joint development and global launch (Sept 24, 2021, U.S. time) of the "Twist–AnchorDx Methylation Pan-Cancer Detection" product. Subsequent Guangzhou Huangpu District International Science & Technology Cooperation project (up to ¥2M funding) titled "Development and Application of an AI-Assisted Diagnostic System Based on Liquid Biopsy cfDNA Methylation High-Throughput Sequencing for Pan-Cancer Detection". The partnership leverages Twist's silicon-chip DNA synthesis platform with AnchorDx's methylation wet lab and AI capabilities.

4Guangdong Provincial People's Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Co-participant in the "R&D and Application of Lung Cancer Precision Early Screening Technology" project, awarded ¥5M of funding in the 2022 Guangzhou Key R&D Program Health Care Major S&T Special Project (led by Guangzhou Medical University First Affiliated Hospital).

anchordx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Joint development and clinical validation of the PulmoPath™ methylation test on bronchoalveolar lavage fluid (BALF) and biopsy tissue samples, achieving 84.1% sensitivity and 92.5% positive predictive value. Co-published in Clinical Epigenetics (2021, IF=7.259), and resulted in a 2022 patent application transfer agreement covering the co-developed IP.

6Harbin Medical University Cancer Hospital (庞达 Professor team)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Joint breast cancer early diagnosis research program. Co-published a foundational Nature sub-journal paper in npj Breast Cancer (CAS Q1) on "Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis", and presented a 2022 SABCS poster on the combined breast ultrasound + ctDNA methylation model for BI-RADS 4a patients (improved accuracy by 40.58%, reduced unnecessary biopsy/surgery by 43.47%).

anchordx.com
7Johnson & Johnson (Lung Cancer Initiative / LCI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Co-led Angel Program (NCT04462185), a prospective observational study with 6 clinical centers enrolling 3,000 patients with indeterminate pulmonary nodules (5-30 mm). The collaboration was used to validate clinical, imaging, and molecular biomarkers in lung cancer and improve diagnostic efficiency for IPN patients. Obtained HGRAC approval in August 2020.

anchordx.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-01-01
Description

Strategic cooperation reached with Illumina (the global leader in genetic sequencing technology) in 2019. This complements the deep Illumina DNA of AnchorDx's R&D team, including founder Dr. Jianbing Fan (Illumina founding employee #23) and CSO Dr. Marina Bibikova (former Illumina chief scientist), both of whom helped build Illumina's BeadArray technology and the first FDA-certified high-throughput sequencing platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Jointly established the "Nankai University – AnchorDx Medical Data Research Center" in 2019. The center co-developed the DeepMeth deep-learning methylation representation model, accepted at AAAI'22 (the 36th AAAI Conference on AI), and is now deployed in 94+ hospitals in China for PulmoSeek Plus. The relationship underpins AnchorDx's AI+methylation research pipeline.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Reached an exclusive patent licensing and cooperation agreement in 2018, expanding AnchorDx's methylation IP base and providing access to Fred Hutch's translational oncology expertise.

11Guangzhou Medical University First Affiliated Hospital / National Respiratory Medical Center (何建行/梁文华 Professor team)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Long-term clinical research partnership co-developing the PulmoSeek and PulmoSeek Plus ctDNA methylation + CT AI products for pulmonary nodule benign/malignant classification. Led multi-center trials including NCT03181490 (PulmoSeek validation, 14 centers, 1,490 subjects) and the Thunder Project (NCT03651986, 23 centers, 10,560 subjects), and won a ¥5M Guangzhou R&D grant in 2022 for the "R&D and Application of Lung Cancer Precision Early Screening Technology" project.

anchordx.com
12Zhong Nanshan (钟南山) / National Respiratory Medical Center – Thunder Project
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Académician Zhong Nanshan-led "Thunder Project" (NCT03651986), a prospective observational study with 23 clinical centers and 10,560 participants with 5-30 mm pulmonary nodules, designed to comprehensively evaluate the combined clinical, AI-assisted CT imaging, and NGS-based ctDNA methylation biomarker model. The project was launched in September 2018, completed enrollment in May 2021, and resulted in multiple peer-reviewed publications and conference presentations.

anchordx.com
13Sun Yat-sen Memorial Hospital, Sun Yat-sen University (黄健 / 林天歆 Professor team)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Five-year collaboration (2017-2022) to develop the UriFind® urine DNA methylation diagnostic product. Resulted in two foundational journal publications (J Clin Invest 2020; Clin Epigenetics 2021) and the BC004 Program (NCT04314245), the first prospective, real-world, multi-center clinical study for urothelial cancer registered with the NIH by a Chinese company. The product led to NMPA Class III approval in 2024.

anchordx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1GRAIL
TypeDirect peer
Description

GRAIL's Galleri test is a methylation-based cfDNA multi-cancer early-detection assay; both companies compete in blood-based methylation cancer screening with overlapping KOL and guideline-endorsement strategies.

TypeBroad incumbent
Description

Guardant360 and Guardant Reveal are liquid-biopsy oncology products; Guardant is a broader liquid-biopsy incumbent pursuing methylation-augmented multi-cancer detection, making it a key adjacency to AnchorDx's pipeline.

TypeDirect peer
Description

Singlera is a Chinese methylation-based cancer screening company (e.g., ColonES) and is one of the closest direct Chinese competitors to AnchorDx's blood-based early-detection platform.

TypeBroad incumbent
Description

Burning Rock is a leading China NGS oncology company offering both cancer therapy selection and early-detection products; comparable to AnchorDx as a China oncology genomics peer with overlapping hospital sales channels.

5Genetron Holdings
TypeDirect peer
Description

Genetron offers NGS-based cancer screening and diagnostics in China, including methylation-based LDT products; competes directly with AnchorDx in the Chinese precision oncology early-detection segment.

TypeOthers
Description

Cologuard and Oncotype DX maker pursuing multi-cancer screening (Cancerguard MCED); a broad U.S. cancer screening incumbent whose methylation work overlaps with AnchorDx's approach.

TypeDirect peer
Description

Freenome is a multiomics (methylation + protein) blood-based multi-cancer screening developer; directly comparable as a privately held MCED peer leveraging ctDNA methylation.

TypeOthers
Description

DiaCarta is AnchorDx's U.S. co-development and global commercialization partner; it also independently develops QClamp®, OptiSeq™, and QuantiVirus™ molecular diagnostics, making it both a partner and a thematically adjacent molecular diagnostics peer.

TypeRegional player
Description

Novogene is a major China-headquartered NGS services and oncology genomics company; comparable as a Chinese sequencing-services peer with overlapping ctDNA sequencing capabilities.

TypeRegional player
Description

Berry Genomics is a leading Chinese genetic testing and cancer diagnostics company (NIPT pioneer expanding into oncology); comparable as a Chinese molecular diagnostics peer with hospital channel overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AnchorDx

Cancer Diagnosticsanchordx.com

AnchorDx is a Guangzhou-based precision medicine company developing ctDNA and cfDNA methylation-based liquid biopsy tests for early cancer detection, serving hospitals and patients across bladder, urothelial, lung, breast, and gastric cancer indications in China and globally.

What AnchorDx does

AnchorDx is a precision medicine company headquartered in Guangzhou, China, founded in 2015. The company develops liquid biopsy tests based on cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) methylation sequencing for early cancer detection, with products built on a "one tube of blood" or "one tube of urine" sample workflow. Its commercial lead product is UriFind, a urine-based test for bladder and urothelial cancer, supported by PulmoSeek Plus for lung cancer and an expanding pipeline covering gastric (Gastromia) and breast cancers, plus a Twist Bioscience-enabled pan-cancer product.

The underlying technology stack combines wet-lab methylation sequencing with proprietary AI-driven classification. AnchorDx operates four named technology platforms — AnchorIRIS, AnchorViola, AnchorMonarch, and DeepMeth — supporting methylation profiling, NGS-based sequencing, bioinformatics analysis, and machine-learning-based cancer classification. The company maintains two R&D centers (Guangzhou, China, and Fremont, California) and two GMP/ISO 13485-certified production facilities. It has filed 82 patent applications with 32 granted, and its PulmoInsight algorithm was trained on more than 20,000 cases and presented at AAAI 2022.

Commercially, AnchorDx operates a hybrid business model: B2B sales of IVD kits to tertiary hospitals (100+ hospitals for UriFind, 94 for PulmoSeek Plus), laboratory-developed test (LDT) services through its own lab, and a direct-to-consumer (DTC) testing service that has cumulatively served over 100,000 people. Revenue mechanics are split across IVD kit unit sales, per-test LDT fees, and DTC test pricing. The company holds NMPA Class III IVD approval (Feb 2024), FDA Breakthrough Device Designation (July 2021), and EU CE Mark, and is pursuing a US PMA trial. It has raised approximately $83M cumulatively, including a $40M Series C in 2021, and entered a global distribution partnership with DiaCarta in February 2024.

AnchorDx firmographics

Firmographics
Name
AnchorDx
Legal name
广州市基准医疗有限责任公司 (Guangzhou AnchorDx Medical Co., Ltd.)
Website
https://anchordx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
AnchorDx is a Guangzhou-based precision medicine company developing ctDNA and cfDNA methylation-based liquid biopsy tests for early cancer detection, serving hospitals and patients across bladder, urothelial, lung, breast, and gastric cancer indications in China and globally.
Ownership category
akta.pro rank

AnchorDx industry classification

Industry
Product category
Cancer Diagnostics
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAD
Cellomics & High-Content Screening (HCS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Cancer early detection
  • DNA methylation diagnostics
  • Liquid biopsy tests
  • IVD reagent kits
  • Clinical laboratory services

Where AnchorDx is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

AnchorDx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure, Others

Revenue model

  1. IVD Reagent Kit Sales (UriFind®): Sale of the "Human ONECUT2/VIM Gene Methylation Test Kit (Fluorescent PCR Method)" (国械注准20243400221), China's first NMPA Class III-approved IVD kit for urothelial cancer auxiliary diagnosis, launched in early 2024. Distributes via commercial channels to hospitals and clinical labs in China. One-time product/license sale per unit.
  2. Clinical Laboratory Testing Services (LDT): AnchorDx Clinical Laboratory (Guangzhou), established 2016, performs DNA methylation-based early cancer detection testing services (LDT mode) for lung, bladder, urothelial, and other cancers. Authorized in 2017 to apply high-throughput sequencing to clinical applications (one of the first such approved labs in China). Per-test service revenue from hospitals, clinicians, and direct consumers.
  3. Direct-to-Consumer Cancer Screening Tests: Online/offline ordering of UriInstant™ (尿立检) and UriFind® (泌益检) urine-based bladder cancer screening and diagnostic products, with home self-sampling kits and 100ml urine collection; includes report interpretation and follow-up services. Per-test usage-based revenue from individual consumers.
  4. Global Out-licensing and Co-Commercialization: Long-term partnership with DiaCarta for joint development and global commercialization of cancer screening products in the U.S. and other markets. Generates licensing royalties, milestone payments, and/or co-commercialization revenue as UriFind® and other products proceed through U.S. PMA and ex-China approvals.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing; customers contact via 400 hotline or online order to obtain per-test and per-kit prices for UriFind/UriInstant screening products
OtherOne time/ perpetual licenseQuote-based IVD kit pricing for hospital/lab buyers of the UriFind® ONECUT2/VIM methylation test kit (NMPA Class III)

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

AnchorDx product offering

Product offering

Core offering

AnchorDx is a precision medicine company that develops and commercializes DNA methylation-based in-vitro diagnostic (IVD) kits and laboratory-developed tests (LDT) for non-invasive early detection of cancer. Its portfolio covers more than 70% of high-incidence cancers through "a tube of blood" products (e.g., PulmoSeek Plus for lung nodules) and "a tube of urine" products (e.g., UriFind for urothelial carcinoma and UriInstant for bladder cancer screening), supported by its in-house clinical laboratory and AI imaging tools. The company is anchored by three proprietary technology platforms — AnchorIRIS methylation library prep, AnchorViola somatic mutation library prep, and AnchorMonarch methylation analysis software — combined with the DeepMeth deep-learning model and PulmoInsight CT AI.

Product overview

AnchorDx (广州市基准医疗有限责任公司) operates a single integrated cancer-early-detection platform built on two diagnostic "lines" — "a tube of blood" and "a tube of urine" — that together cover more than 70% of high-incidence cancers. The portfolio is unified by three proprietary technology pillars — AnchorIRIS® (methylation library prep), AnchorViola® (somatic-mutation library prep) and AnchorMonarch® (AI-driven methylation analysis software) — and is delivered through three product families: (1) the Respiratory / Lung-nodule line, led by the flagship PulmoSeek™ Plus (费益检®) blood-based methylation + CT-imaging AI test, complemented by PulmoPath™ (费镜检™) for bronchoalveolar lavage and PulmoInsight™ (费影检™) for CT-imaging AI; (2) the Urinary / Urothelial-cancer line, led by UriFind® (泌益检™) — China's first NMPA-approved IVD for urothelial cancer auxiliary diagnosis (Class III, Feb 2024) — and the early-screening test UriInstant™ (尿立检™); and (3) the Digestive / Gastric-cancer pipeline, anchored by Gastromia™ (胃易检). AnchorDx also co-developed a pan-cancer methylation assay with Twist Bioscience, runs the AnchorDx Clinical Laboratory for centralized LDT service, and uses its Guangzhou International Bio Island facilities plus a US R&D center in Fremont, California, to drive both domestic commercialization and global registration.

Differentiator

Problem solved

Functional benefit

Brands

  • PulmoSeek™ Plus (费益检®): Non-invasive liquid biopsy combined with CT imaging AI to distinguish benign and malignant pulmonary nodules. ctDNA methylation-based diagnostic product.
  • UriFind® (泌益检™)
  • UriFind™ / UriInstant™ (尿立检™)
  • PulmoPath™ (费镜检™)
  • PulmoInsight™ (费影检™)
  • Gastromia™ (胃易检)
  • AnchorIRIS®
  • AnchorViola®
  • AnchorMonarch®

Products and services

  • UriFind® (泌益检) — Human ONECUT2/VIM Gene Methylation Test Kit A urine-based DNA methylation test (ONECUT2/VIM gene methylation, fluorescent PCR method) for non-invasive auxiliary diagnosis of urothelial carcinoma (bladder, ureteral, and renal pelvis cancers). Requires 100 ml of random urine. NMPA Class III-approved, US FDA Breakthrough Device Designation, EU IVDD CE Mark. Sold to hospitals and clinical labs in China and to global partners.
  • UriInstant™ (尿立检) — Urothelial Cancer Early Screening Test Non-invasive urine-based genetic test for early screening of urothelial tumors covering three urinary tract cancers (bladder urothelial carcinoma, renal pelvis carcinoma, ureteral carcinoma). Designed for at-home self-sampling. Performance validated in approximately 20,000 real-world cases. Available through hospital orders and direct-to-consumer online/offline ordering.
  • PulmoSeek™ Plus (费益检®) — Pulmonary Nodule Benign/Malignant Test Non-invasive liquid biopsy test combining 10 ml peripheral blood ctDNA methylation (NGS) with chest CT-imaging AI to differentially diagnose benign vs malignant pulmonary nodules of 5–30 mm. Sensitivity 98.1%, specificity 91.7%, accuracy 97.3%. Sample: 10 ml blood + CT-DICOM data. ISO 13485:2016 certified; EU IVDD CE Mark. Sold to hospitals, with direct-to-consumer ordering available.
  • PulmoPath™ (费镜检™) — Early Lung Cancer BALF/Biopsy Methylation Test Early lung cancer auxiliary methylation test for bronchoalveolar lavage fluid (BALF) and biopsy tissue samples, designed to improve the diagnostic yield of bronchoscopy and percutaneous lung biopsy. Sensitivity 84.1%, positive predictive value 92.5%. Co-developed with West China Hospital, Sichuan University.
  • PulmoInsight™ (费影检™) — AI Lung Nodule CT Imaging Analysis CT-imaging AI software that automatically detects, segments, tracks, and risk-stratifies pulmonary nodules. Trained on 20,000+ pathologically confirmed lung nodule CT cases. Reports 95% detection rate, approximately 30-second automated analysis, and 0.001 mm³ volume precision. Accepts CT-DICOM input; intended for pulmonary nodule patients and LDCT screening populations.
  • AnchorDx Clinical Laboratory (Guangzhou) — LDT Clinical Testing Service High-standard clinical laboratory on Guangzhou International Bio Island performing DNA methylation-based cancer early-screening and early-diagnosis testing services for lung, bladder, urothelial, and other cancers. Has passed NCCL/CAP proficiency testing for six consecutive years. Serves hospitals, clinicians, and individual consumers.
  • Gastromia™ (胃易检) — Gastric Cancer Non-invasive Methylation Assay Non-invasive blood-based ctDNA methylation assay for early detection of gastric cancer built on a 7-marker methylation panel. Overall sensitivity 87.3%, specificity 66.2%, 99.6% NPV at 2% prevalence, 80% sensitivity for early-stage gastric cancer. Co-developed with Guangdong Provincial People's Hospital and Southern Medical University.
  • Twist–Anchor Methylation Pan-Cancer Detection Product Pan-cancer cfDNA methylation high-throughput sequencing assay co-developed with Twist Bioscience, launched globally. Combines Twist's silicon-chip DNA synthesis platform with AnchorDx's methylation wet lab and AI capabilities.

Quantifiable outcome

  • PulmoSeek Plus: 98.1% sensitivity, 91.7% specificity, 97.3% accuracy for pulmonary nodule benign/malignant classification
  • +9 more outcomes

Companies that use AnchorDx

Customer profile

Segments5 records

Ideal customer profiles4 records

AnchorDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

AnchorDx partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship and core.

  • DiaCarta (帝基生物)flagshipStrategic or Co-development Partner · 1 February 2024Long-term collaboration between AnchorDx and DiaCarta (Pleasanton, CA) for joint product development and global commercialization of cancer screening tests, leveraging complementary DNA methylation (AnchorDx) and mutation detection (DiaCarta QClamp®, XNA-NGS OptiSeq™) technologies. DiaCarta is also a clinical testing laboratory in AnchorDx's U.S. UriFind® PMA registrational trial (NCT05643690). The partnership is part of AnchorDx's stated strategy to accelerate global commercialization of UriFind® and future cancer screening products.
  • U.S. Urology and Clinical Centers (10 sites) + 3 CAP/CLIA laboratories for UriFind® PMA trialcoreImplementation/ SI/ Consulting Partner · 1 January 2023AnchorDx's U.S. registrational clinical trial (NCT05643690) for UriFind® PMA application plans to enroll more than 1,000 patients across 10 urology centers and 3 CAP/CLIA-certified laboratories (DiaCarta is one of them), with first patient enrolled. Trial results will be submitted to the U.S. FDA for Premarketing Approval.
  • Twist Bioscience (拓唯思特, NASDAQ: TWST)coreStrategic or Co-development Partner · 1 February 2022Joint development and global launch (Sept 24, 2021, U.S. time) of the "Twist–AnchorDx Methylation Pan-Cancer Detection" product. Subsequent Guangzhou Huangpu District International Science & Technology Cooperation project (up to ¥2M funding) titled "Development and Application of an AI-Assisted Diagnostic System Based on Liquid Biopsy cfDNA Methylation High-Throughput Sequencing for Pan-Cancer Detection". The partnership leverages Twist's silicon-chip DNA synthesis platform with AnchorDx's methylation wet lab and AI capabilities.
  • Guangdong Provincial People's HospitalcoreStrategic or Co-development Partner · 1 January 2022Co-participant in the "R&D and Application of Lung Cancer Precision Early Screening Technology" project, awarded ¥5M of funding in the 2022 Guangzhou Key R&D Program Health Care Major S&T Special Project (led by Guangzhou Medical University First Affiliated Hospital).
  • West China Hospital, Sichuan University (刘丹/李为民 Professor team)coreStrategic or Co-development Partner · 1 January 2021Joint development and clinical validation of the PulmoPath™ methylation test on bronchoalveolar lavage fluid (BALF) and biopsy tissue samples, achieving 84.1% sensitivity and 92.5% positive predictive value. Co-published in Clinical Epigenetics (2021, IF=7.259), and resulted in a 2022 patent application transfer agreement covering the co-developed IP.
  • Harbin Medical University Cancer Hospital (庞达 Professor team)coreStrategic or Co-development Partner · 1 January 2021Joint breast cancer early diagnosis research program. Co-published a foundational Nature sub-journal paper in npj Breast Cancer (CAS Q1) on "Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis", and presented a 2022 SABCS poster on the combined breast ultrasound + ctDNA methylation model for BI-RADS 4a patients (improved accuracy by 40.58%, reduced unnecessary biopsy/surgery by 43.47%).
  • Johnson & Johnson (Lung Cancer Initiative / LCI)coreStrategic or Co-development Partner · 1 January 2020Co-led Angel Program (NCT04462185), a prospective observational study with 6 clinical centers enrolling 3,000 patients with indeterminate pulmonary nodules (5-30 mm). The collaboration was used to validate clinical, imaging, and molecular biomarkers in lung cancer and improve diagnostic efficiency for IPN patients. Obtained HGRAC approval in August 2020.
  • IlluminacoreTechnology or Integration · 1 January 2019Strategic cooperation reached with Illumina (the global leader in genetic sequencing technology) in 2019. This complements the deep Illumina DNA of AnchorDx's R&D team, including founder Dr. Jianbing Fan (Illumina founding employee #23) and CSO Dr. Marina Bibikova (former Illumina chief scientist), both of whom helped build Illumina's BeadArray technology and the first FDA-certified high-throughput sequencing platform.
  • Nankai University (南开大学)coreStrategic or Co-development Partner · 1 January 2019Jointly established the "Nankai University – AnchorDx Medical Data Research Center" in 2019. The center co-developed the DeepMeth deep-learning methylation representation model, accepted at AAAI'22 (the 36th AAAI Conference on AI), and is now deployed in 94+ hospitals in China for PulmoSeek Plus. The relationship underpins AnchorDx's AI+methylation research pipeline.
  • Fred Hutchinson Cancer Research CentercoreStrategic or Co-development Partner · 1 January 2018Reached an exclusive patent licensing and cooperation agreement in 2018, expanding AnchorDx's methylation IP base and providing access to Fred Hutch's translational oncology expertise.
  • Guangzhou Medical University First Affiliated Hospital / National Respiratory Medical Center (何建行/梁文华 Professor team)flagshipStrategic or Co-development Partner · 1 January 2017Long-term clinical research partnership co-developing the PulmoSeek and PulmoSeek Plus ctDNA methylation + CT AI products for pulmonary nodule benign/malignant classification. Led multi-center trials including NCT03181490 (PulmoSeek validation, 14 centers, 1,490 subjects) and the Thunder Project (NCT03651986, 23 centers, 10,560 subjects), and won a ¥5M Guangzhou R&D grant in 2022 for the "R&D and Application of Lung Cancer Precision Early Screening Technology" project.
  • Zhong Nanshan (钟南山) / National Respiratory Medical Center – Thunder ProjectflagshipStrategic or Co-development Partner · 1 January 2017Académician Zhong Nanshan-led "Thunder Project" (NCT03651986), a prospective observational study with 23 clinical centers and 10,560 participants with 5-30 mm pulmonary nodules, designed to comprehensively evaluate the combined clinical, AI-assisted CT imaging, and NGS-based ctDNA methylation biomarker model. The project was launched in September 2018, completed enrollment in May 2021, and resulted in multiple peer-reviewed publications and conference presentations.
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University (黄健 / 林天歆 Professor team)flagshipStrategic or Co-development Partner · 1 January 2017Five-year collaboration (2017-2022) to develop the UriFind® urine DNA methylation diagnostic product. Resulted in two foundational journal publications (J Clin Invest 2020; Clin Epigenetics 2021) and the BC004 Program (NCT04314245), the first prospective, real-world, multi-center clinical study for urothelial cancer registered with the NIH by a Chinese company. The product led to NMPA Class III approval in 2024.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

AnchorDx competitors and assessment

Company assessment

Direct peers

  • GRAIL: GRAIL's Galleri test is a methylation-based cfDNA multi-cancer early-detection assay; both companies compete in blood-based methylation cancer screening with overlapping KOL and guideline-endorsement strategies.
  • Singlera Genomics: Singlera is a Chinese methylation-based cancer screening company (e.g., ColonES) and is one of the closest direct Chinese competitors to AnchorDx's blood-based early-detection platform.
  • Genetron Holdings: Genetron offers NGS-based cancer screening and diagnostics in China, including methylation-based LDT products; competes directly with AnchorDx in the Chinese precision oncology early-detection segment.
  • Freenome: Freenome is a multiomics (methylation + protein) blood-based multi-cancer screening developer; directly comparable as a privately held MCED peer leveraging ctDNA methylation.

Broad incumbents

  • Guardant Health: Guardant360 and Guardant Reveal are liquid-biopsy oncology products; Guardant is a broader liquid-biopsy incumbent pursuing methylation-augmented multi-cancer detection, making it a key adjacency to AnchorDx's pipeline.
  • Burning Rock Biotech: Burning Rock is a leading China NGS oncology company offering both cancer therapy selection and early-detection products; comparable to AnchorDx as a China oncology genomics peer with overlapping hospital sales channels.

Others

  • Exact Sciences: Cologuard and Oncotype DX maker pursuing multi-cancer screening (Cancerguard MCED); a broad U.S. cancer screening incumbent whose methylation work overlaps with AnchorDx's approach.
  • DiaCarta: DiaCarta is AnchorDx's U.S. co-development and global commercialization partner; it also independently develops QClamp®, OptiSeq™, and QuantiVirus™ molecular diagnostics, making it both a partner and a thematically adjacent molecular diagnostics peer.

Regional players

  • Novogene: Novogene is a major China-headquartered NGS services and oncology genomics company; comparable as a Chinese sequencing-services peer with overlapping ctDNA sequencing capabilities.
  • Berry Genomics: Berry Genomics is a leading Chinese genetic testing and cancer diagnostics company (NIPT pioneer expanding into oncology); comparable as a Chinese molecular diagnostics peer with hospital channel overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AnchorDx compliance and trust

Trust signal

Compliance11 records

AnchorDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AnchorDx leadership team

Management profile

Number of profiles

Profiles4 records

AnchorDx subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

AnchorDx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AnchorDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AnchorDx

What does AnchorDx do?

AnchorDx is a precision medicine company that develops and commercializes DNA methylation-based in-vitro diagnostic (IVD) kits and laboratory-developed tests (LDT) for non-invasive early detection of cancer. Its portfolio covers more than 70% of high-incidence cancers through "a tube of blood" products (e.g., PulmoSeek Plus for lung nodules) and "a tube of urine" products (e.g., UriFind for urothelial carcinoma and UriInstant for bladder cancer screening), supported by its in-house clinical laboratory and AI imaging tools. The company is anchored by three proprietary technology platforms — AnchorIRIS methylation library prep, AnchorViola somatic mutation library prep, and AnchorMonarch methylation analysis software — combined with the DeepMeth deep-learning model and PulmoInsight CT AI.

Is AnchorDx a public or private company?

AnchorDx is a private company. It is classified as venture growth investor backed and is currently operating.

When was AnchorDx founded?

AnchorDx was founded in 2015. It employs 11 to 50 people.

Where is AnchorDx based?

AnchorDx is headquartered in Guangzhou, China, in the Asia region.

How does AnchorDx make money?

Four revenue lines are on record. IVD Reagent Kit Sales (UriFind®) is the primary driver. The others are clinical Laboratory Testing Services (LDT), direct-to-Consumer Cancer Screening Tests and global Out-licensing and Co-Commercialization.

Who are AnchorDx's main competitors?

Direct peers on record are GRAIL, Singlera Genomics, Genetron Holdings and Freenome. Broad incumbents are Guardant Health and Burning Rock Biotech. Others are Exact Sciences and DiaCarta. Regional players are Novogene and Berry Genomics.

Does AnchorDx have an API?

No public API is recorded for AnchorDx.

What industry is AnchorDx in?

AnchorDx's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TipranksKindstar Narrows Loss as It Bets on Oncology and CRO Growth Amid Industry HeadwindsKindstar Globalgene Technology reported 2025 revenue of RMB933.6 million, up 0.65% year on year, as it navigated industry-wide adjustments in China's third-party medical testing sector amid tighter medical insurance cost controls and increased lab result recognition. The company's net loss narrowed to RMB55.1 million, helped by cost-efficiency measures and investment fair value gains, though gross profit fell 6.53% and gross margin declined to 44.0% from 47.4% due to ramp-up costs from new units and pricing pressure. Kindstar also announced board guidelines for dividend distribution from 2025 to 2027 and proposed governance changes as it expands into early tumor screening and CRO services through acquisitions like AnchorDx.GlobeNewswireLiquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and OncimmuneThe global liquid biopsy for early cancer detection and monitoring market was estimated at USD 2.23 billion in 2024 and is projected to reach USD 6.20 billion by 2033, a CAGR of 12.14%. Growth is driven by rising cancer incidence and demand for non-invasive diagnostics, with challenges including assay standardization and reimbursement.BioSpaceAnchorDx Appoints Dr. Marina Bibikova as Chief Scientific OfficerAnchorDx appointed Dr. Marina Bibikova as Chief Scientific Officer, responsible for cancer early detection technology, global IVD registrations, and strategic partnerships. She brings over 25 years of genomics experience, including leading Illumina's MiSeqDx submission, and will accelerate AnchorDx's overseas product registration and global commercialization.PR NewswireAnchorDx Appoints Dr. Marina Bibikova as Chief Scientific OfficerAnchorDx, a Guangzhou-based developer of cancer screening and early detection solutions, announced the appointment of Dr. Marina Bibikova as Chief Scientific Officer on March 6, 2022. Dr. Bibikova brings over 25 years of genomics experience, having led Illumina's MiSeqDx sequencer 510(K) submission, the first in vitro diagnostic next-generation sequencing instrument cleared by the U.S. FDA, and will be responsible for cancer early detection technology development, global IVD registrations, and international patent strategy. The appointment is intended to accelerate AnchorDx's overseas product registration and global business development in the early tumor detection industry.PR NewswireAnchorDx Achieves Academic Breakthrough with Deep Methylation Representation Learning Research Paper Accepted by 36th AAAI ConferenceAnchorDx, a Guangzhou-based developer of cancer screening solutions, announced on December 1, 2021, that its research paper on "Deep Methylation Representation Learning" (DeepMeth) was accepted at the 36th AAAI Conference on Artificial Intelligence, out of a record 9,251 submissions with only a 15% acceptance rate. The paper, jointly submitted with Nankai University's Advanced Medical Data Research Center, introduces one of the world's first deep learning models to represent ctDNA methylation regions by continuous vectors and serves as the core algorithm for AnchorDx's lung cancer early diagnosis product, PulmoSeek™ Plus. The technology has been clinically applied to patients from 94 hospitals since April 2020 and demonstrated satisfactory performance, with the company publishing related research in The Journal of Clinical Investigation earlier this year.PR NewswireAnchorDx Develops New Liquid Biopsy Diagnostic Model for Early Detection of Breast CancerAnchorDx, a Chinese biotechnology company, jointly published research with experts from a top-tier hospital in China in the journal npj Breast Cancer on a new liquid biopsy diagnostic model using circulating cell-free DNA (cfDNA) methylation patterns for early breast cancer detection. The diagnostic model demonstrated 94.79% sensitivity and 98.70% specificity in clinical validation (n=229 total samples), outperforming mammography with an AUROC of 0.9815 versus 0.9315. The company plans to collect additional case and testing data to further validate the model for potential clinical use, particularly for high-risk women in China.BioWorldAnchordx wins FDA’s breakthrough device designation for bladder cancer testThe FDA granted Anchordx Medical's Urifind, an early bladder cancer detection test, a breakthrough device designation. This is the first BTD for a liquid biopsy test for bladder cancer in China, supporting Anchordx's upcoming IPO.PR NewswireAnchorDx's Non-invasive Bladder Cancer Early Detection Test, UriFind, Earns "Breakthrough Device Designation" from FDAAnchorDx was awarded Breakthrough Device Designation by the US FDA on July 13, 2021, for UriFind, a non-invasive bladder cancer early detection test based on urine DNA methylation detection. This is the first BTD granted to a liquid biopsy test for bladder cancer detection in China, with the test demonstrating 89.3% accuracy, 87.4% sensitivity, and 91.5% specificity in clinical validation. The test has been included in China's 2021 Guidelines for Diagnosis and Treatment of Bladder Cancer and has received EU CE marking, with US clinical trials slated to launch and four-year Medicare coverage expected upon FDA market authorization.